Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers. Lead programs include ALLO-715, an anti-BCMA therapy for multiple myeloma, and ALLO-501, which targets CD19 for non-Hodgkin lymphoma and other B-cell malignancies. Allogene applies proprietary TALEN gene-editing to disrupt the endogenous T-cell receptor and other genes, reducing the risk of graft-versus-host disease and enabling repeat dosing possibilities.
Headquartered in South San Francisco, California, Allogene collaborates with global partners to advance its off-the-shelf portfolio. A strategic alliance with Servier grants the European-based pharmaceutical company exclusive ex-U.S. rights to develop and commercialize select Allogene candidates. This partnership supports clinical development across North America, Europe and other key oncology markets.
Founded in 2017 as a spin-out from Kite Pharma, Allogene Therapeutics went public in 2020 to support the rapid advancement of its clinical programs. The company is led by President and Chief Executive Officer David Chang, whose background spans immuno-oncology research and strategic biotech leadership. Under his direction, Allogene aims to establish allogeneic CAR T as a new standard in cell-based cancer treatment.
AI Generated. May Contain Errors.
